BOULDER, Colo., May 17, 2022--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present virtually at the H.C. Wainwright Global Investment Conference being held May 23-25, 2022.
BOULDER, Colo., May 12, 2022--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at the American Thoracic Society (ATS) 2022 International Conference. The meeting will take place May 13-18, 2022, in San Francisco, California.
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -31.58% and 2.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?